Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis

Molecular Cancer Therapeutics

Volumn 3, Issue 1, 2004, Pages 71-84

  Jazirehi, Ali R ^a   Bonavida, Benjamin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL X; PROTEIN BID; PROTEIN MCL 1; REGULATOR PROTEIN; RESVERATROL; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRANSCRIPTION FACTOR AP 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INDUCTION; ENZYME METABOLISM; ENZYME RELEASE; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOGENESIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RESISTANCE; UPREGULATION;

EID: 4444274529     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.71.3.1     Document Type: Article

References (73)

1. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3:1041-64.
2. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemoimmuno-sensitizing activities. Curr Med Chem Anti-Cancer Agents. 2003;3:77-93.
3. Bhat KPL, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann NY Acad Sci. 2002;957:210-29.
4. Roemer K, Mahyar-Roemer M. The basis for the chemopreventive action of resveratrol. Drugs Today. 2002;38:571-80.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218-20.
6. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 1998;273:21875-82.
7. Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, Roti JL, et al. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett. 2002;175:165-73.
8. Moreno JJ. Resevratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J Pharmacol Exp Ther. Conference. 2000;294:333-8.
9. Martinez J, Moreno JJ. Effect of Resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol. 2000;59:865-70.
10. 1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 2001;7:1466-73.
11. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002;8:893-903.
12. Dörrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001;61:4731-9.
13. Ferreria CG, Epping M, Kruyt FAE, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8:2024-34.
14. Bebawy M, Morris MB, Roufogalis BD. Selective modulation of P-glycoprotein-mediated drug resistance. Br J Cancer. 2001;85:1998-2003.
15. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192:768-80.
16. Sandor V, Wilson W, Fojo T, Bates SE. The role of MDR-1 in refractory lymphoma. Leuk Lymphoma. 1997;28:23-31.
17. Emmanouilides C, Jazirehi A, Bonavida B. Rituximab-mediated sensitization of non-Hodgkin's lymphoma (NHL) B-cells to cytotoxicity induced by paclitaxel, gemcitabine and vinorelbine. Cancer Biother Radiopharm. 2002;17:621-30.
18. Goss P, Stewart AK, Couture F, Klasa R, Gluck S, Kaizer L, et al. Combined results of two phase II studies of taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 1999;34: 295-304.
19. Miller HJ, Leong T, Khandekar JD, Greipp PR, Gertz MA, Kyle RA. Paclitaxel as the initial treatment of multiple myeloma: an Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 1998;21:553-6.
20. Jazirehi AR, Ng C-P, Gan X-H, Schiller G, Bonavida B. Adriamycin sensitized the Adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/TRAIL-mediated apoptosis. Clin Cancer Res. 2001;7: 3874-83.
21. Ng C-P, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res. 2002;85:145-74.
22. Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. An EBV-genome-negative cell line established from an American Burkitt's lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 1975;5:319-34.
23. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug-resistant human myeloma cell line that express P-glycoprotein. Cancer Res. 1986;46:5125-30.
24. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 1995;92:7686-9.
25. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995;270:27489-94.
26. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623-32.
27. Tzung S-P, Kim CM, Basanez G, Giedt CD, Simon J, Zimmerberg J, et al. Antimycin A mimics a cell death-inducing Bcl-2 homology domain 3. Nat Cell Biol. 2001;3:183-91.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271.
29. L and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2003;2:1183-93.
30. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and Bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res. 2000;60:1645-53.
31. Birch DE. Simplified hot start PCR. Nature (Lond). 1996;381:445-6.
32. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis. 1978;137:122.
33. Scaffidi C, Fluda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17: 1675-87.
34. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with mAbs. Blood. 1998;91:1644-52.
35. Lee JT Jr., McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia. 2002;16:486-507.
36. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updates. 2001;5:253-67.
37. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270(28):16483-6.
38. L protein by Ets, Rel/NF-κB, STAT and AP-1 transcription factor families. Histol Histopathol. 2001;16:595-601.
39. Rowinsky EK, Donehower RC. Antimicrotubule agents. Cancer chemo-therapy and biotherapy. 2nd ed. Chabner BA, Longo DL, editors. Philadelphia: Lippincott-Raven Publishers; 1996. p. 263-90.
40. Collins K, Jacks T, Paveltich NP. The cell cycle and cancer. Proc Natl Acad Sci USA. 1997;94:2776-8.
41. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem Biophys Res Commun. 1999;254: 739-43.
42. Cain K, Bratton SB, Cohen GM. The Apaf-1 apoptosome: a large caspase-activating complex. Biochemie. 2002;84:203-14.
43. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res. 1998;58:4561-6.
44. Narayanan BA, Narayanan NK, Stoner GD, Bullock BP. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxiclants. Life Sci. 2002;70:1821-39.
45. Kudla G, Montessuit S, Eskes R, Berrier C, Martinou JC, Ghazi A, et al. The destabilization of lipid membranes induced by the C-terminal fragment of caspase-8 cleaved Bid is inhibited by the N-terminal fragment. J Biol Chem. 2000;275:22713-8.
46. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000; 7:1166-73.
47. De Feudis P, Vignati S, Rossi C, Mincioni T, Giavazzi R, D'Incalci M, et al. Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. Neoplasia. 2000;2: 202-7.
48. Tsuruta Y, Mandai M, Konishi I, Kuroda H, Kusakari T, Yura Y, et al. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur J Cancer. 2001;37:531-41.
49. Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood. 2002;100: 217-23.
50. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA. 1996;93:14094-9.
51. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res. 1998;58:4776-81.
52. Mahyar-Roemer M, Katsen A, Mestres P, Roemer K. Resveratrol induces tumor cell apoptosis independently of p53 and precedes by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer. 2001;94:615-22.
53. Roucou X, Rostovtseva T, Montessuit S, Martinou JC, Antonsson B. Bid induces cytochrome c-impermeable Bax channels in liposomes. Biochem J. 2002;363:547-52.
54. Krajewska M, Zapata JM, Meinhold-Heerlein I, Hedayat H, Monks A. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia. 2002;4:129-40.
55. Nakagawa H, Kiyozuka Y, Uemura Y, Shikata N, Hioki K, Tsubura A. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic avid, a potent breast cancer cell stimulator.J Cancer Res Clin Oncol. 2001;127:258-64.
56. L overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of acute myeloid leukemia HL-60 cells. Cancer Res. 1997;57:1109-16.
57. El-Mowafy AM, White RE. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett. 1999;451:63-7.
58. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99:1885-93.
59. Pagnano KB, Silva MD, Vassallo J, Aranha FJ, Saad ST. Apoptosis-regulating proteins and prognosis in diffuse large B cell non-Hodgkin's lymphomas. Acta Haematol. 2002;107:29-34.
60. Rassidakis GZ, Lai R, McDonnell TJ, Cabanilla F, Sarris AH, Mederios LJ. Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol. 2002;160:2309-10.
61. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential protein of human myeloma cells. Blood. 2002;100:194-9.
62. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 2002;99:1038-43.
63. Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol. 2001;62: 1469-80.
64. Huang HM, Huang CJ, Yen JJ. Mcl-1 is a common target of stem cell factor and IL-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/AKT pathways. Blood. 2000;96:1764-71.
65. Schubert KM, Duroino V. Distinct roles of extracellular-signal-regulated protein kinase (ERK) mitogen activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis. Biochem J. 2001;356:473-80.
66. MacKeigan JP, Collins TS, Ting JP-Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000;275:38953-6.
67. Dai Y, Yu C, Sing V, Tang L, Wang Z, Molinstry R, et al. Pharmacological inhibitors of the mitogen activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61:5106-15.
68. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16:6914-25.
69. Deveraux QL, Roy N, Stennicke HR, Arsdale TV, Zhou Q, Srinivasula SM, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215-23.
70. Bernardi P, Scorrano L, Colonna R, Petronilli V, Di Lisa F. Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem. 1999;264:687-701.
71. Scorrano L, Petronilli V, Colonna R, Di Lisa F, Bernardi P. Chloromethyl-tetramethylrosamine (Mitotracker Orange) induces the mitochondrial permeability transition and inhibits respiratory complex I. Implications for the mechanism of cytochrome c release. J Biol Chem. 1999;274: 24657-63.
72. Scorrano L, Ashiya M, Buttle K, Weiler S, Oakes SA, Mannella CA, et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell. 2002;2:55-67.
73. Waterhouse NJ, Ricci JE, Green DR. And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochemie. 2002;84:113-21.